TICKERNERD
Menu
TNXPTNXPHealthcare · Biotechnology

TNXP Stock Forecast: Tonix Pharmaceuticals Holding Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$13
+1.45% on the day

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. hold a median 12-month price target of $34 — +170.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$215.6M
Ticker Nerd rank
22 / 100
Median analyst target
$34
Analysts covering
4
Total return, dividends reinvested
1W
−1.1%
1M
+8.7%
YTD
−19.5%
1Y
−64.9%
From 52W high
−66.9%
From 52W low
+32.2%
$10
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tonix Pharmaceuticals Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
22 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
67
Quality
64
Revisions
60
Growth
42
Volatility
34
Accruals
34
Value
20
Issuance
16
Momentum
6

Size (67): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TNXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26TNXPHigh $65Median $34Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $22Median $34High $65

The green dot is the last close — the median target sits +170.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 June 2026Raymond JamesInitiatesStrong Buy$26
4 May 2026TD CowenInitiatesBuy—
20 Mar 2025Noble Capital MarketsReiteratesOutperform—
22 July 2024Alliance Global PartnersMaintainsBuy—
28 Feb 2024Dawson JamesInitiatesBuy—
1 Aug 2023Alliance Global PartnersMaintainsBuy—
2 June 2023Alliance Global PartnersMaintainsBuy—
12 Jan 2023Alliance Global PartnersReiteratesBuy$6.50
18 Apr 2022Noble Capital MarketsInitiatesOutperform$0.60
31 Aug 2021Alliance Global PartnersMaintainsBuy—
11 Aug 2021Alliance Global PartnersMaintainsBuy—
25 Feb 2021Alliance Global PartnersMaintainsBuy—
18 Nov 2019B. Riley FBRDowngradeNeutral—
18 Nov 2019Cantor FitzgeraldDowngradeHold—
18 Nov 2019Janney CapitalInitiatesBuy—
18 Nov 2019OppenheimerMaintainsOutperform—
18 Nov 2019Roth CapitalUpgradeBuy—
18 Apr 2019Roth CapitalUpgradeBuy—
27 July 2018B. Riley FBRDowngradeNeutral—
27 July 2018Roth CapitalDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TNXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tonix Pharmaceuticals Holding Corp. (TNXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
7.4×

Cheaper than 18% of US stocks

Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
577.9%

Higher than 98% of US stocks

Earnings growth (YoY)
183.2%

Higher than 89% of US stocks

Gross margin
77.1%

Higher than 89% of US stocks

Operating margin
−314.1%

Higher than 9% of US stocks

Net margin
49.3%

Higher than 96% of US stocks

Returns & dividend
Return on equity
−81.8%

Higher than 15% of US stocks

Return on assets
−46.8%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TNXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNXPTonix Pharmaceuticals Holding Corp.$215.6M
22
PEPGPepGen Inc.$215.8M
43
KROSKeros Therapeutics, Inc.$217.5M
71
CHRSCoherus Oncology, Inc.$212.2M
55
ANTXAN2 Therapeutics, Inc.$208.8M
74
IMUXImmunic, Inc.$224.8M
38
NERVMinerva Neurosciences, Inc.$225.5M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tonix Pharmaceuticals Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNXP news & analysis

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

MarketBeat · 18 Aug 2026positive

Tonix Pharmaceuticals CEO Seth Lederman presented the company's near-term strategy during a Canaccord Genuity conference, highlighting the commercial launch of TONMYA for fibromyalgia along with advancing development programs in Lyme disease prevention and major depressive disorder.

Why it matters — TNXP watchers would care because the update outlines the company's strategic priorities around its commercial product and pipeline direction.

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Tonix Pharmaceuticals Holding Corp. held its second-quarter 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. No other details were provided in this item.

Why it matters — A Tonix watcher would look to the earnings-call transcript for the company's own commentary on its quarterly results and outlook.

Tonix Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026positive

Tonix Pharmaceuticals reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of its fibromyalgia treatment Tonmya. Tonmya sales rose 197% from the first quarter in its second full quarter of commercial sales following the product's November launch.

Why it matters — This marks the second full quarter of Tonmya commercial sales, showing strong quarter-over-quarter growth in the company's lead product revenue.

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

GlobeNewsWire · 10 Aug 2026positive

Tonix Pharmaceuticals reported second quarter 2026 financial results and operational highlights. TONMYA net sales totaled approximately $11 million, up 197% quarter-over-quarter, with payer coverage expanding to roughly 136 million covered lives (43% of U.S. lives). The company enrolled its first patient in the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, and its Phase 2 field study of TNX-4800 for Lyme disease prevention remains on track to start in Q1 2027 pending FDA review. Cash and cash equivalents stood at approximately $176.2 million as of June 30, 2026.

Why it matters — The strong quarter-over-quarter growth in TONMYA sales, expanded payer coverage, and progress across both pipeline programs provide TNXP watchers with key evidence of commercial traction and near-term catalysts.

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire · 5 Aug 2026neutral

Tonix Pharmaceuticals announced that its management team will participate in two upcoming investor conferences scheduled for August and September 2026. The announcement was made by the fully integrated, commercial-stage biotechnology company on August 5, 2026.

Why it matters — TNXP watchers may view this as the company engaging with the investment community to present its business at upcoming investor conferences.

FAQ

Frequently asked questions about TNXP stock

What is the TNXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Tonix Pharmaceuticals Holding Corp. have a median 12-month price target of $34, with estimates ranging from $22 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNXP stock a buy right now?

Of the 4 analysts covering Tonix Pharmaceuticals Holding Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tonix Pharmaceuticals Holding Corp. 22 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNXP?

As at 22 Aug 2026, Tonix Pharmaceuticals Holding Corp. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (67 of 100).

Will TNXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +170.5% from the last close, and Ticker Nerd's factor model ranks Tonix Pharmaceuticals Holding Corp. 22 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNXP stock forecast for 2030?

No analyst covering Tonix Pharmaceuticals Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $65 over the next 12 months.

How has TNXP stock performed over the past year?

Tonix Pharmaceuticals Holding Corp. returned -64.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tonix Pharmaceuticals Holding Corp. do?

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering.

What is the latest news on TNXP?

The most recent item we track (MarketBeat, 18 Aug 2026): "Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline". Tonix Pharmaceuticals CEO Seth Lederman presented the company's near-term strategy during a Canaccord Genuity conference, highlighting the commercial launch of TONMYA for fibromyalgia along with advancing development programs in Lyme disease prevention and major depressive disorder.

Company

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its primary emphasis is on central nervous system (CNS) disorders, including fibromyalgia and major depressive disorder, addressed by product candidates like TNX-102 SL, a sublingual cyclobenzaprine HCl tablet branded as TONMYA, now available by prescription as the first new FDA-approved fibromyalgia treatment in over 15 years. The company also markets Zembrace SymTouch and Tosymra for acute migraine treatment in adults. In immunology, it advances biologics such as TNX-1500, a humanized monoclonal antibody targeting CD40-ligand for organ transplant rejection, autoimmunity, and cancer. Additional pipelines cover infectious diseases like mpox and Lyme disease prevention with TNX-801 and TNX-4800, respectively, rare diseases including Prader-Willi Syndrome via TNX-2900, and other areas. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals Holding Corp. operates in the biotechnology sector, targeting unmet medical needs across multiple therapeutic domains.

CEO Dr. Seth Lederman M.D. · 142 employees · United States · https://www.tonixpharma.com